表紙
市場調査レポート

消化管間質腫瘍 (GIST):パイプライン製品の分析

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229743
出版日 ページ情報 英文 209 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
消化管間質腫瘍 (GIST):パイプライン製品の分析 Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 209 Pages
概要

消化管間質腫瘍 (GIST) とは、消化管に生じる腫瘍の一種です。軟部組織肉腫とよばれるがんの一群に属し、良性腫瘍の場合もあれば、悪性の場合もあります。主な症状として、腹部の疼痛や不快感、手で触って感じられる腹部のかたまり、吐き気・嘔吐、吐血、血の混じった排便、頭痛に伴う倦怠感(赤血球不足)などが挙げられます。主な治療法には、外科手術や放射線治療、標的療法、化学療法などが含まれています。

当レポートでは、世界各国での消化管間質腫瘍 (GIST) 治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

消化管間質腫瘍 (GIST)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

消化管間質腫瘍 (GIST):企業で開発中の治療薬

消化管間質腫瘍 (GIST):大学/機関で研究中の治療薬

消化管間質腫瘍 (GIST):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

消化管間質腫瘍 (GIST):企業で開発中の製品

消化管間質腫瘍 (GIST):大学/機関で研究中の製品

消化管間質腫瘍 (GIST)の治療薬開発に従事している企業

  • AB Science SA
  • Advenchen Laboratories, LLC
  • Ariad Pharmaceuticals, Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Boston Biomedical, Inc.
  • Calithera Biosciences, Inc.
  • Chipscreen Biosciences Ltd
  • Deciphera Pharmaceuticals, LLC
  • F. Hoffmann-La Roche Ltd.
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kolltan Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Omeros Corporation
  • Plexxikon Inc.
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.

消化管間質腫瘍 (GIST):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

消化管間質腫瘍 (GIST):最近のパイプライン動向

消化管間質腫瘍 (GIST):休止中のプロジェクト

消化管間質腫瘍 (GIST):開発が中止された製品

消化管間質腫瘍 (GIST):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8038IDB

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016', provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
  • The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects
  • The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastrointestinal Stromal Tumor (GIST) Overview
  • Therapeutics Development
    • Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
    • Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
  • Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
  • Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Advenchen Laboratories, LLC
    • Ariad Pharmaceuticals, Inc.
    • Arog Pharmaceuticals, Inc.
    • Array BioPharma Inc.
    • Astex Pharmaceuticals, Inc.
    • Blueprint Medicines Corporation
    • Boston Biomedical, Inc.
    • Calithera Biosciences, Inc.
    • Chipscreen Biosciences Ltd
    • Deciphera Pharmaceuticals, LLC
    • F. Hoffmann-La Roche Ltd.
    • Horizon Pharma Plc
    • Immunicum AB
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Kolltan Pharmaceuticals, Inc.
    • Natco Pharma Limited
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • Omeros Corporation
    • Plexxikon Inc.
    • TG Therapeutics, Inc.
    • Threshold Pharmaceuticals, Inc.
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BB-503 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BLU-285 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-839 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CHMFLKIT-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-2164 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DCC-2618 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evofosfamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • infigratinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon gamma-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Intuvax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTN-0158 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMSP-088 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NRCAN-019 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onalespib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-9486 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponatinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SF-1126 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHR-1020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGR-1202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vemurafenib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
  • Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting
      • Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285
      • Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
      • Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting
      • Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
      • Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican
      • Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig
      • Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors
      • Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting
      • Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2016
  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics, Inc., H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2016
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2016
  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top